SK Biopharmaceuticals has settled a U.S. patent lawsuit with Indian generic drugmaker MSN Laboratories over Xcopri, its epilepsy drug containing cenobamate, ending the case pending before the U.S. District Court for the District of Delaware. Financial and other detailed terms were not disclosed, but the deal grants MSN the right to launch a generic version in the future, subject to SK Biopharmaceuticals' patent protection and the settlement conditions. The dispute centered on follow-on patents rather than Xcopri's core compound patent, which expires in 2032. SK Biopharmaceuticals said those additional patents were designed to extend protection beyond the compound patent's expiry. The actual launch date for MSN's generic has not been set and may depend on U.S. regulatory approval procedures and the confidential terms of the settlement. The company said the agreement is meaningful for its long-term U.S. market defense strategy as Xcopri prescriptions grow, helping it manage uncertainty around generic competition while preserving a more stable commercialization window. It also described the deal as the first agreement reached among its ongoing patent disputes.